BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 20107719)

  • 1. Pruritus in cutaneous T-cell lymphomas: frequent, often severe and difficult to treat.
    Meyer N; Paul C; Misery L
    Acta Derm Venereol; 2010; 90(1):12-7. PubMed ID: 20107719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What's New in Cutaneous T-Cell Lymphoma-Associated Pruritus.
    Biazus Soares G; Guitart J; Yosipovitch G
    Am J Clin Dermatol; 2024 Jan; 25(1):67-77. PubMed ID: 37971624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma.
    Demierre MF; Taverna J
    J Am Acad Dermatol; 2006 Sep; 55(3):543-4. PubMed ID: 16908377
    [No Abstract]   [Full Text] [Related]  

  • 4. Aprepitant improves refractory pruritus in primary cutaneous T-cell lymphomas: experience of the Spanish Working Group on Cutaneous Lymphomas.
    Maroñas-Jiménez L; Estrach T; Gallardo F; Pérez A; Andrés Borja H; Servitje O; Pérez Gala S; Linares Barrio M; Jiménez Gallo D; Sanz-Bueno J; Lora D; Monsálvez V; Ortiz-Romero PL
    Br J Dermatol; 2018 Apr; 178(4):e273-e274. PubMed ID: 29150837
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma.
    Whittaker SJ; Foss FM
    Cancer Treat Rev; 2007 Apr; 33(2):146-60. PubMed ID: 17275192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma.
    Marolleau JP; Baccard M; Flageul B; Rybojad M; Laroche L; Vérola O; Brandely M; Morel P; Gisselbrecht C
    Arch Dermatol; 1995 May; 131(5):574-9. PubMed ID: 7741545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on treatment of cutaneous T-cell lymphoma.
    Gardner JM; Evans KG; Musiek A; Rook AH; Kim EJ
    Curr Opin Oncol; 2009 Mar; 21(2):131-7. PubMed ID: 19532014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pruritus in Cutaneous T-Cell Lymphoma and Its Management.
    Serrano L; Martinez-Escala ME; Zhou XA; Guitart J
    Dermatol Clin; 2018 Jul; 36(3):245-258. PubMed ID: 29929596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cutaneous lymphoma of the Sézary and Bouvrain type. Progress in physiopathologic and therapeutic outlook].
    Bagot M
    Bull Acad Natl Med; 1998; 182(5):927-37; discussion 937-8. PubMed ID: 9735499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. United States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemic.
    Zic JA; Ai W; Akilov OE; Carter JB; Duvic M; Foss F; Girardi M; Gru AA; Kim E; Musiek A; Olsen EA; Schieke SM; Shinohara M; Zain JM; Geskin LJ
    J Am Acad Dermatol; 2020 Aug; 83(2):703-704. PubMed ID: 32305443
    [No Abstract]   [Full Text] [Related]  

  • 11. Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma.
    Booken N; Heck M; Nicolay JP; Klemke CD; Goerdt S; Utikal J
    Br J Dermatol; 2011 Mar; 164(3):665-7. PubMed ID: 21039410
    [No Abstract]   [Full Text] [Related]  

  • 12. Pruritus measurement and treatment.
    Langner MD; Maibach HI
    Clin Exp Dermatol; 2009 Apr; 34(3):285-8. PubMed ID: 19309370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pruritus in cutaneous T-cell lymphoma: a review.
    Ahern K; Gilmore ES; Poligone B
    J Am Acad Dermatol; 2012 Oct; 67(4):760-8. PubMed ID: 22285672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aprepitant in the treatment of refractory pruritus secondary to cutaneous T-cell lymphoma.
    Borja-Consigliere HA; López-Pestaña A; Vidal-Manceñido MJ; Tuneu-Valls A
    Actas Dermosifiliogr; 2014 Sep; 105(7):716-8. PubMed ID: 24139470
    [No Abstract]   [Full Text] [Related]  

  • 15. Memorials and mandates for cutaneous lymphomas.
    Heald PW
    Arch Dermatol; 2003 Jul; 139(7):926-8. PubMed ID: 12873891
    [No Abstract]   [Full Text] [Related]  

  • 16. [Current therapy concepts in cutaneous T-cell lymphomas].
    Nestle FO; Häffner AC; Schmid MH; Dummer R; Burg G
    Schweiz Med Wochenschr; 1997 Feb; 127(8):311-20. PubMed ID: 9157537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational therapy for cutaneous T-cell lymphomas in the 1990s. Fact or fancy?
    Bunn PA
    Arch Dermatol; 1995 May; 131(5):603-5. PubMed ID: 7537952
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of pruritus in early-stage hypopigmented mycosis fungoides with aprepitant.
    Jiménez Gallo D; Albarrán Planelles C; Linares Barrios M; Fernández Anguita MJ; Márquez Enríquez J; Rodríguez Mateos ME
    Dermatol Ther; 2014; 27(3):178-82. PubMed ID: 24517320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update on mechanisms of pruritus and their potential treatment in primary cutaneous T-cell lymphoma.
    Hu M; Scheffel J; Elieh-Ali-Komi D; Maurer M; Hawro T; Metz M
    Clin Exp Med; 2023 Dec; 23(8):4177-4197. PubMed ID: 37555911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutaneous T-cell lymphoma: overview and nursing perspectives.
    McCann SA
    Nurs Clin North Am; 2007 Sep; 42(3):421-55, vi-vii. PubMed ID: 17825663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.